2022
Are patients with alcohol-related cancers (ARCs) more likely to quit drinking than the general population? Results of a national population-based survey.
Ishani K, Chagpar A. Are patients with alcohol-related cancers (ARCs) more likely to quit drinking than the general population? Results of a national population-based survey. Journal Of Clinical Oncology 2022, 40: e18716-e18716. DOI: 10.1200/jco.2022.40.16_suppl.e18716.Peer-Reviewed Original ResearchAlcohol-related cancersGeneral populationAnnual household incomeNational Health Interview Survey (NHIS) datasetHeavy drinkersNational population-based surveyThird of patientsRisk of recurrencePopulation-based surveyCurrent heavy drinkersVariety of cancersProportion of peopleIndependent predictorsPrivate health insuranceHigh school educationPatientsSociodemographic factorsMultivariate analysisPublic insuranceHousehold incomeCancerHealth insuranceDrinkersLower ratesDrinkingDoes perceived stigma or shame affect stage of presentation in Iraqi Kurdish women diagnosed with breast cancer?
Chagpar A, Qader S, Baqri M, Khoshnood K, Ahmed H. Does perceived stigma or shame affect stage of presentation in Iraqi Kurdish women diagnosed with breast cancer? Journal Of Clinical Oncology 2022, 40: e18680-e18680. DOI: 10.1200/jco.2022.40.16_suppl.e18680.Peer-Reviewed Original ResearchStage 1 diseaseBreast cancerStage diseaseStage 1 breast cancerHigher stage diseaseLate-stage diseaseStage of presentationCancer Stigma ScaleMonthly household incomeBCSS scoreMost patientsCancer patientsBreast centerPatientsStigma ScaleFeelings of shameFeelings of stigmaCancerDiseaseWomenPossible scoreMarital statusIraqi womenDiagnosisStage 1
2019
Factors associated with breast cancer mortality-per-incident case in low-to-middle income countries (LMICs).
Chagpar A, Coccia M. Factors associated with breast cancer mortality-per-incident case in low-to-middle income countries (LMICs). Journal Of Clinical Oncology 2019, 37: 1566-1566. DOI: 10.1200/jco.2019.37.15_suppl.1566.Peer-Reviewed Original Research
2018
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.Peer-Reviewed Original ResearchSurgical Management of the Breast
Chagpar A. Surgical Management of the Breast. DeckerMed Complex General Surgical Oncology 2018 DOI: 10.2310/7800.16006.Peer-Reviewed Original ResearchSentinel node biopsySurgical managementAxillary dissectionNode biopsyBreast cancerBreast surgical oncologyKey clinical trialsNode-positive diseaseBreast-conserving surgeryCompletion dissectionBreast conservationRadical mastectomyClinical trialsSurgical oncologyRadiation therapyLeading malignancyCancerDissectionMastectomyBiopsyMalignancyKey wordsChemotherapyManagementSurgerySurgical Management of the Breast
Chagpar A. Surgical Management of the Breast. DeckerMed CGSO Case-Based Reviews 2018 DOI: 10.2310/cgso.16006.Peer-Reviewed Original ResearchSentinel node biopsySurgical managementAxillary dissectionNode biopsyBreast cancerBreast surgical oncologyKey clinical trialsNode-positive diseaseBreast-conserving surgeryCompletion dissectionBreast conservationRadical mastectomyClinical trialsSurgical oncologyRadiation therapyLeading malignancyCancerDissectionMastectomyBiopsyMalignancyKey wordsChemotherapyManagementSurgery
2017
Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer.
Hofstatter E, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Patwardhan G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. DOI: 10.1200/jco.2017.35.15_suppl.1522.Peer-Reviewed Original ResearchNormal breast tissueBreast cancerBreast tissueHealthy peersSusan G. Komen Tissue BankIU Simon Cancer CenterNormal breast tissue samplesBreast cancer preventionCohort of womenImportant risk factorKomen Tissue BankLifetime of womenBreast tissue samplesCurrent medicationsTumor characteristicsCancer CenterRisk factorsCancer preventionClinical dataFamily historyReduction mammoplastyHigh riskChronologic ageReproductive historyCancer
2016
Impact of a pre-operative exercise intervention on Ki-67 and metabolic markers in women with early breast cancer.
Ligibel J, Giobbie-Hurder A, Shockro L, Rhei E, Troyan S, Dominici L, Chagpar A, Frank E, McTiernan A, Yung R, Freedman R, Tolaney S, O'Connor K, Stecker K, Dillon D, Irwin M. Impact of a pre-operative exercise intervention on Ki-67 and metabolic markers in women with early breast cancer. Journal Of Clinical Oncology 2016, 34: 564-564. DOI: 10.1200/jco.2016.34.15_suppl.564.Peer-Reviewed Original Research
2015
Characteristics and treatment of Her2 positive breast cancer: 43,485 cases from the National Cancer Database (NCDB) treated in 2010 and 2011
Killelea B, Chagpar A, Horowitz N, Lannin D. Characteristics and treatment of Her2 positive breast cancer: 43,485 cases from the National Cancer Database (NCDB) treated in 2010 and 2011. Journal Of The American College Of Surgeons 2015, 221: e4. DOI: 10.1016/j.jamcollsurg.2015.08.310.Peer-Reviewed Original ResearchCan routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM).
Chagpar A, Killelea B, Tsangaris T, Butler M, Stavris K, Yao X, Li F, Bossuyt V, Pusztai L, Horowitz N. Can routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM). Journal Of Clinical Oncology 2015, 33: 1012-1012. DOI: 10.1200/jco.2015.33.15_suppl.1012.Peer-Reviewed Original ResearchEpidemiology of Ductal Carcinoma In Situ
Kanumuri P, Chagpar A. Epidemiology of Ductal Carcinoma In Situ. 2015, 1-11. DOI: 10.1007/978-1-4939-2035-8_1.Peer-Reviewed Original ResearchSurgical Management of Hereditary Breast Cancer
Plasilova M, Chagpar A. Surgical Management of Hereditary Breast Cancer. Current Breast Cancer Reports 2015, 7: 43-47. DOI: 10.1007/s12609-014-0169-5.Peer-Reviewed Original Research
2013
State of the Art in Imaging and Chemoprevention for High-Risk Patients
Hofstatter E, Andrejeva L, Chagpar A. State of the Art in Imaging and Chemoprevention for High-Risk Patients. Current Breast Cancer Reports 2013, 5: 125-133. DOI: 10.1007/s12609-013-0104-1.Peer-Reviewed Original ResearchBreast cancer preventionCancer preventionBreast cancerAccurate breast cancer risk assessmentAppropriate breast cancer screeningBreast cancer risk assessmentChemoprevention clinical trialsHigh-risk patientsBreast cancer screeningPromising new optionCancer risk assessmentCancer screeningClinical trialsPractical updatePatientsEarly detectionCancerPreventionNew optionsRiskRisk assessmentChemopreventionOptionsBreastClinicians
2012
The effect of family history on adherence to breast cancer screening guidelines.
Hibler L, Chagpar A. The effect of family history on adherence to breast cancer screening guidelines. Journal Of Clinical Oncology 2012, 30: 1571-1571. DOI: 10.1200/jco.2012.30.15_suppl.1571.Peer-Reviewed Original ResearchNational Health Interview SurveyMale breast cancerFemale breast cancerBreast cancerFamily historyBreast cancer screening guidelinesCancer screening guidelinesUse of mammographyHealth Interview SurveyPast yearIndependent predictorsScreening guidelinesNHIS dataUS populationMultivariate analysisCancerDisease controlInterview SurveyWomenAdherenceHigher likelihoodMammographyPersonal historyAgeGuidelinesAccuracy of breast MRI in predicting pathologic tumor size.
Caprio K, Chagpar A, Hooley R, Tavassoli F, Honarpishe H, Lannin D, Killelea B, Horowitz N. Accuracy of breast MRI in predicting pathologic tumor size. Journal Of Clinical Oncology 2012, 30: 1109-1109. DOI: 10.1200/jco.2012.30.15_suppl.1109.Peer-Reviewed Original ResearchPathologic tumor sizeTumor sizeAccuracy of MRIMRI sizePathologic sizePathology sizeBreast cancerMRI lesion sizeSitu breast cancerPreoperative planning toolFinal pathologyNeoadjuvant chemotherapyPatient agePathologic findingsTumor histologyPreoperative MRILesion sizeLesionsBreast MRISpearman's rho coefficientPatientsMRICancerModest correlationSpearman coefficient
2011
Factors Affecting Survival Following First Locoregional Recurrence After Surgically Managed Breast Cancer
Crutcher C, Chagpar A. Factors Affecting Survival Following First Locoregional Recurrence After Surgically Managed Breast Cancer. Journal Of Surgical Research 2011, 165: 178. DOI: 10.1016/j.jss.2010.11.737.Peer-Reviewed Original ResearchIntraoperative Considerations in Sentinel Lymph Node Biopsy for Breast Cancer
Chagpar A. Intraoperative Considerations in Sentinel Lymph Node Biopsy for Breast Cancer. TouchREVIEWS In Oncology & Haematology 2011, 07: 111. DOI: 10.17925/ohr.2011.07.2.111.Peer-Reviewed Original ResearchSentinel lymph node biopsyLymph node biopsyNode biopsySLN-positive patientsAxillary node dissectionIsolated tumor cellsBreast cancer patientsBreast cancer managementNode dissectionSLN biopsyCancer patientsIntraoperative considerationsSurgical techniqueBreast cancerCancer managementTumor cellsBiopsyPatientsSubject of debateMicrometastasesLymphCancerMainstaySLNsDissection
2010
Sentinel Lymph Node Biopsy May Not Be Necessary in All Patients Undergoing Prophylactic Mastectomy But Should Be Considered in Patients with Inflammatory Breast Cancer and/or Extensive Ipsilateral Axillary Disease
Nasser S, Smith S, Chagpar A. Sentinel Lymph Node Biopsy May Not Be Necessary in All Patients Undergoing Prophylactic Mastectomy But Should Be Considered in Patients with Inflammatory Breast Cancer and/or Extensive Ipsilateral Axillary Disease. Journal Of Surgical Research 2010, 158: 263-264. DOI: 10.1016/j.jss.2009.11.260.Peer-Reviewed Original Research
2009
QS103. Quantitative Galactose Oxidase Schiff Reaction in Nipple Aspirate Fluid May Distinguish Women With or Without Breast Cancer
Chagpar A, Clements K, Carte C, McMasters K, Evelegh M. QS103. Quantitative Galactose Oxidase Schiff Reaction in Nipple Aspirate Fluid May Distinguish Women With or Without Breast Cancer. Journal Of Surgical Research 2009, 151: 287. DOI: 10.1016/j.jss.2008.11.399.Peer-Reviewed Original Research
2008
Use of adjuvant chemotherapy in young women with node-negative ER+ breast cancer: Refining the use of recurrence score—A decision analysis
Woodall C, Reuter N, Scoggins C, Martin R, McMasters K, Hargis J, Chagpar A. Use of adjuvant chemotherapy in young women with node-negative ER+ breast cancer: Refining the use of recurrence score—A decision analysis. Journal Of Clinical Oncology 2008, 26: 11547-11547. DOI: 10.1200/jco.2008.26.15_suppl.11547.Peer-Reviewed Original Research